Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

telaprevir Articles

Vertex also gains US FDA approval for hep C drug Incivek

24 May 2011

US FDA clears first hep C drug in a decade, Merck & Co’s Victrelis

16 May 2011

Priority reviews for Vertex’ hep C candidate telaprevir in USA and Canada

21 January 2011

Vertex maintains 2010 outlook, reveals launch plan for hep C drug telaprevir and progress of other programs

11 January 2011

Merck & Co’s hep C drug candidate boceprevir gets expedited review in USA and EU

7 January 2011

Liver disease meeting hears updates on Merck & Co’s boceprevir, Boehringer Ingelheim’s HCV combo, Vertex’ telaprevir and Gilead’s Viread

2 November 2010

75% of treatment-naive chronic hepatitis C patients achieve SVR with Vertex’ telaprevir in Ph III trial

27 May 2010

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • CIS countries prepare for the introduction of drug reimbursement schemes
  • Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • CIS countries prepare for the introduction of drug reimbursement schemes
  • Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS